EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis

Albert Aboseif iD, Georgios Mangioris, Binxia Yang, Vanessa K Pazdernik, Jeffrey W Britton, Divyanshu Dubey iD, Eoin P Flanagan, Sarosh R Irani iD, Gregory S Day iD, Charles L Howe iD, A Sebastian López-Chiriboga, Andrew McKeon iD und 6 weitere

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Albert Aboseif und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Cytokines, Neurofilament Proteins, Chemokines, Autoimmune Diseases of the Nervous System. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Roche/Genentech, Center for MS and Autoimmune Neurology, Mayo Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the value of cytokine, chemokine, and neurofilament light chain (NfL) concentrations in predicting relapse risk, chronic epilepsy, and functional impairment in LGI1 autoimmune encephalitis (AE).

Methods

Cytokines/chemokines (IL‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8/CXCL8, IL‐10, IL‐12p70, IL‐13, IL‐17A, GM‐CSF, TNF‐alpha, IFN‐gamma, CXCL9, CXCL10, CXCL13, BAFF) and NfL concentrations were measured in CSF and paired serum from LGI1‐AE patients evaluated at Mayo Clinic (01/2015–02/2024), using a multiplex immunoassay system (ELLA, Bio‐Techne) and correlated with clinical outcomes. A laboratory‐based cohort of LGI1‐IgG‐positive patients and control cohorts, including patients with mixed non‐inflammatory disorders (MNID), Alzheimer's disease (AD), and temporal lobe epilepsy (TLE) were analyzed.

Results

Forty‐four patients with LGI1‐AE were included; 29 (66%) were male, with a median age of 68.5 years (range, 8–85). Median time from symptom onset to CSF sampling was eight months (IQR, 3–17); 19/42 (45%) experienced a clinical relapse and 27% developed chronic epilepsy. Serum IL‐6, serum and CSF IL‐8/CXCL8, and IL‐17A were higher in LGI1‐IgG positive patients than MNID ( p < 0.05). TLE cytokine/chemokine profiles were similar to LGI1 AE; AD patients had lower serum IL‐6 and CSF IL‐8/CXCL8 ( p = 0.04; p = 0.01), and higher serum IL‐17A and GM‐CSF ( p = 0.004; p = 0.01) than LGI1‐AE. Higher CSF IL‐6 and IL‐8/CXCL8 in LGI1‐AE associated with clinical relapse ( p < 0.05) and higher CSF NfL associated with chronic epilepsy ( p = 0.01).

Conclusion

Elevations in IL‐6, IL‐8/CXCL8, and IL‐17A were identified in this LGI1‐AE cohort. CSF IL‐6, IL‐8/CXCL8, and NfL levels are potential prognostic biomarkers for risk of relapse and chronic epilepsy in LGI1‐AE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytokinesNeurofilament ProteinsChemokinesAutoimmune Diseases of the Nervous SystemEncephalitisIntracellular Signaling Peptides and ProteinsHumansMaleFemaleMiddle AgedAdultAgedYoung AdultBiomarkersAutoantibodiesAdolescent

Stichwörter der Autor:innen

Leucine‐rich glioma‐inactivated‐1autoimmune seizuresbiomarkersepilepsyfaciobrachial dystonic seizures

Substanzen

CytokinesLGI1 protein, humanneurofilament protein LNeurofilament ProteinsChemokinesBiomarkersAutoantibodiesIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
  • Center for Multiple Sclerosis & Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Nuffield Department of Clinical Neurosciences, Oxford Autoimmune Neurology Group, University of Oxford, Oxford, UK.

ORCID-Profile: Albert Aboseif, Divyanshu Dubey, Sarosh R Irani, Gregory S Day, Charles L Howe, Andrew McKeon, Sean J Pittock, Anastasia Zekeridou

Förderung

  • NINDS NIH HHS
  • Roche/Genentech
  • Center for MS and Autoimmune Neurology, Mayo Clinic
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Aboseif, A., Mangioris, G., Yang, B., Pazdernik, V. K., Britton, J. W., Dubey, D., Flanagan, E. P., Irani, S. R., Day, G. S., Howe, C. L., López-Chiriboga, A. S., McKeon, A., Mills, J. R., Segal, Y., Toledano, M., Vodopivec, I., Pittock, S. J., & Zekeridou, A. (2025). Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70158

Vancouver

Aboseif A, Mangioris G, Yang B, Pazdernik VK, Britton JW, Dubey D, et al. Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70158

BibTeX
@article{Aboseif2025,
  author = {Aboseif, Albert and Mangioris, Georgios and Yang, Binxia and Pazdernik, Vanessa K and Britton, Jeffrey W and Dubey, Divyanshu and Flanagan, Eoin P and Irani, Sarosh R and Day, Gregory S and Howe, Charles L and López-Chiriboga, A Sebastian and McKeon, Andrew and Mills, John R and Segal, Yahel and Toledano, Michel and Vodopivec, Ivana and Pittock, Sean J and Zekeridou, Anastasia},
  title = {Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70158}
}
Kostenlos starten →